Programmed Death-Ligand 1
The PD-L1 test assists physicians in assessing a patient’s potential benefit from immunotherapy, particularly in non-small cell lung cancer (NSCLC), gastric adenocarcinomas, gastroesophageal sphincter adenocarcinomas, urinary tract cancers, and various other malignancies.
The PD-L1 test is intended for the subsequent scenarios:
The preliminary treatment strategy has been finalized, necessitating more therapy alternatives.
Untreated tumors.
Highly malignant tumors that are unresponsive to conventional therapies.
Uncommon neoplasms.
Types of tumors have numerous potential treatment options, such as lung cancer.
Technical Specifications of the PD-L1 Test
- One strategy for combating cancer involves inhibiting the PD-L1 protein, which may obstruct cancer cells from deactivating T lymphocytes via both PD-1 and B7.1. The objective of immunotherapy is to enhance immune system activity to elicit a more potent anticancer response.
- The PD-L1 test is conducted via the immunohistochemistry method to identify PD-L1 protein in formalin-fixed and paraffin-embedded (FFPE) tissue from non-small cell lung cancer (NSCLC), gastric adenocarcinomas, adenocarcinomas of the gastroesophageal sphincter, urinary tract, and various other cancer types.
- For patients whose immunotherapy response requires evaluation, it is advised to assess Immune Response, encompassing the three biomarkers that predict response to TMB immunotherapy: MSI and PD-L1.
The assessment encompasses all cancer types and assists in forecasting patients’ reactions to immunotherapy. The PD-L1 test is predominantly conducted in non-small cell lung cancer (NSCLC), gastric adenocarcinomas, adenocarcinomas of the gastroesophageal junction, urinary tract malignancies, and various other cancer types.
Results are provided within seven business days
A paraffin block containing tumor tissue or unstained paraffin slides.
For cost coverage and information, please contact the Sci-Pharm secretariat by clicking here.
Payments may be executed via bank transfer or Cash.
For inquiries about the sample receipt, please contact the Customer service. The results are communicated to both you and your doctor by email.
